Ultomiris (Ravulizumab)
- Medicine Name: Ultomiris
- Generic Name: Ravulizumab
- Dosage Form & Strength: Injection: 300 mg/30 mL (10 mg/mL) in a single-dose vial
- Manufactured By: Alexion Pharmaceuticals, Inc.
- the treatment of adult and pediatric patients aged one month and older with paroxysmal nocturnal hemoglobinuria (PNH).
- the treatment of adult and pediatric patients aged one month and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
- 5 to less than 10 kg: 600 mg (Loading Dose); 300 mg maintenance dose for every 4 weeks.
- 10 to less than 20 kg: 600 mg (Loading Dose); 600 mg maintenance dose for every 4 weeks.
- 20 to less than 30 mg: 900 mg (Loading Dose); 2,100 mg maintenance dose for every 8 weeks.
- 30 to less than 40 mg: 1,200 mg (Loading Dose); 2,700 mg maintenance dose for every 8 weeks.
- 40 to less than 60 mg: 2,400 mg (Loading Dose); 3,000 mg maintenance dose for every 8 weeks.
- 60 to less than 100 mg: 2,700 mg (Loading Dose); 3,300 mg maintenance dose for every 8 weeks.
- 100 kg or greater: 3,000 mg (Loading Dose); 3,600 mg maintenance dose for every 8 weeks.
- Hazardous meningococcal infections have been seen in patients treated with Ravulizumab. The use of this medicine increases a patient’s risk to catch serious meningococcal infections (septicemia/meningitis). Meningococcal disease because of any serogroup may emerge.
- Immunize patients without a known history of meningococcal vaccination at least 14 days prior to their first Ultomiris dose. If urgent ultomiris 10 mg/ml therapy is needed in an unvaccinated patient, administer meningococcal vaccine(s) as quickly as possible and provide patients with 14 days of antibacterial drug prophylaxis.
- Precisely monitor patients for early signs/symptoms of meningococcal infection and assess patients promptly in case infection is suspected. Inform patients of these signs/symptoms and steps to be considered to seek prompt medical care. Meningococcal infection may quickly become life-threatening or fatal in case not identified and treated early.
- After discontinuing therapy with ultomiris 300 mg/30 ml, closely monitor for signs/symptoms of hemolysis, identified by elevated LDH together with sudden reduction in PNH clone size or hemoglobin, or occurrence of symptoms such as abdominal pain, fatigue, shortness of breath (dyspnea), hemoglobinuria, major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction.
- Use of Ravulizumab injection may result in infusion-related reactions including anaphylaxis and hypersensitivity reactions. These reactions typically do not require interruption of therapy. Interrupt the Ravulizumab infusion and institute apt supportive measures in case signs/symptoms of cardiovascular instability or respiratory compromise appear.
What documents are required to import ULTOMIRIS to India?
ULTOMIRIS (ravulizumab) injection can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients Proof of Identity (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is ULTOMIRIS available in India?
ULTOMIRIS (ravulizumab injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
ULTOMIRIS can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of ULTOMIRIS (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for ultomiris price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the ULTOMIRIS (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Ultomiris®?
Ravulizumab is Generic Name for the trade name drug Ultomiris®.
What is the Manufacturer Name of Ultomiris®?
Ultomiris® is manufactured by Alexion Pharmaceuticals, Inc.
Is Ultomiris® approved by the FDA?
Yes, Ultomiris® is approved by the FDA. Date of first approval: December 21, 2018.
What is the dosage and form of Ultomiris® supplied?
Ultomiris® is supplied as an Injection in three different dosage strength:
300 mg/30 mL (10 mg/mL) in a single-dose vial.
300 mg/3 mL (100 mg/mL) in a single-dose vial.
1,100 mg/11 mL (100 mg/mL) in a single-dose vial.
What are the most common side effects due to Ultomiris®?
Most common side effects due to Ultomiris® in patients with PNH include: upper respiratory tract infection, headache; and in patients with aHUS include diarrhea, upper respiratory tract infection, nausea, hypertension vomiting, headache, and pyrexia
How much does Ripretinib cost in India?
The ultomiris cost in India is very reasonable and can vary. To procure this complement inhibitor authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Ultomiris®?
Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton in order to protect from light. Neither freeze nor shake.
Is it safe to buy Ultomiris® online from India?
Yes, You can buy ultomiris injection from India online authentically from https://www.indianpharmanetwork.in/ if Ultomiris is not available or has not been approved in your home country.
What are the Highlights of prescribing information for Ultomiris®?
Click Here to download full Ultomiris prescribing information
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.